Anti-stathmin gene therapy - Gradalis

Drug Profile

Anti-stathmin gene therapy - Gradalis

Alternative Names: pbi-shRNA STMN1 LP; pbi-shSTMN1 LP

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Gradalis
  • Developer Gradalis; Mary Crowley Cancer Research Center
  • Class Gene therapies
  • Mechanism of Action Stathmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 13 Apr 2017 Strike Bio completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT01505153)
  • 29 Feb 2012 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT01505153)
  • 05 Jul 2011 Preclinical trials in Solid tumours in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top